Aim: To conduct a review of the impact of presenteeism as it relates to the nursing workforce.
Background: Presenteeism behaviour has been researched in the broader workforce across multiple industries including business/management, public health and occupational health. Presenteeism in nursing is particularly significant because it puts patients at risk by reducing the capacity of nurses to provide high quality care. Rates of presenteeism are particularly high in the nursing workforce and the impact of nurse presenteeism needs to be further examined and explored.
Design: An integrative review of the associated literature.
Methods: Online databases were searched for research related to presenteeism in the nursing workforce. Original primary research investigating presenteeism in the nursing workforce, in all clinical settings, in the English language and published between 2006 and 2018 were included.
Results: A total of 17 studies fit the inclusion criteria and were included in this review: 16 quantitative and 1 qualitative. Five categories emerged from the data synthesis process: 1) the prevalence of presenteeism, 2) the economic cost of presenteeism, 3) presenteeism and related health conditions, 4) presenteeism and nurse well-being, and 5) presenteeism and patient safety.
Conclusion: The scale and impact of presenteeism is rarely explicitly discussed. Further research is needed to investigate the link between presenteeism, nurse well-being quality of patient care and costs in the nursing sector.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ijnurstu.2020.103659 | DOI Listing |
Int Nurs Rev
March 2025
College of Nursing, Keimyung University, Daegu, South Korea.
Aim: This study aimed to estimate the annual cost burden of productivity loss due to sickness presenteeism among hospital nurses in South Korea.
Background: Despite nurses being potentially more vulnerable to presenteeism, few studies have analyzed nurses' productivity losses due to sickness presenteeism.
Methods: This cross-sectional study employed an online survey in January 2023 with 607 nurses working in general/tertiary hospitals in South Korea.
BMJ Open
January 2025
Health Economics and Health Technology assessment, School of Health and Wellbeing, University of Glasgow, Glasgow, UK.
Objectives: To identify, measure and value the economic burden of musculoskeletal (MSK) disorders in the Kilimanjaro region, Tanzania.
Design: Community-based cross-sectional survey (undertaken between January and September 2021).
Setting: Hai district, Kilimanjaro, Tanzania.
Workplace Health Saf
January 2025
College of Nursing, Chengdu University of Traditional Chinese Medicine.
Background: Although previous studies suggest a link between workplace bullying and presenteeism, uncertainties persist regarding the direction, strength, and influencing factors. Understanding the potential mediators and moderators is crucial to addressing these issues in workplace settings.
Objective: This study aims to clarify the bidirectional relationship between workplace bullying and presenteeism, assess the strength and direction of this association, and identify individual and work-related factors that mediate or moderate these interactions.
BMC Public Health
January 2025
ZHAW Zurich University of Applied Sciences, School of Health Sciences, Institute of Public Health, Winterthur, Switzerland.
Background: Neck pain is a significant public health issue, especially among office workers, with a prevalence ranging from 42 to 68%. This study aimed to evaluate the cost-utility and cost-benefit of a multi-component intervention targeting neck pain in the general population of office workers in Switzerland. The 12-week multi-component intervention consisted of neck exercises, health promotion information workshops, and workplace ergonomics sessions.
View Article and Find Full Text PDFMaturitas
November 2024
Hormone Hamburg, Hamburg, Germany. Electronic address:
Objective: To report patient-reported quality-of-life (QOL) outcomes in the DAYLIGHT study.
Study Design: DAYLIGHT was a phase 3b, randomized, double-blind, 24-week, placebo-controlled study. Participants were women aged ≥40 to ≤65 years with moderate to severe vasomotor symptoms (VMS) considered unsuitable for hormone therapy (HT) (contraindications, caution, stoppers, or averse) randomized 1:1 to placebo or fezolinetant 45 mg once daily.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!